COMP <GO>
EW vs ABBV // FORWARD P/E MULTIPLE
Edwards Lifesciences Corporation (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: EW 7
— ABBV 8
▲ FORWARD P/E MULTIPLE LEADER: EW
LAST: $92.01 (-2.57%) • MKT CAP: $54.44B
forward-pe
47.2x
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
forward-pe
113.1x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (EW VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | EW | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 78.00% | 70.20% | +7.80 | EW | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 12.50% | 29.00% | -16.50 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 35.1x | 33.3x | +1.80 | ABBV | /valuation <GO> |
| Free Cash Flow Yield | 2.45% | 3.47% | -1.02 | ABBV | /fcf-yield <GO> |
| Operating Margin | 20.80% | 24.60% | -3.80 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 17.70% | 6.90% | +10.80 | EW | /net-margins <GO> |
| Revenue Growth (YoY) | 11.50% | 8.60% | +2.90 | EW | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 12.36 | 5.33 | +7.03 | EW | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | EW | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 7.40% | -0.20 | EW | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 59.9 | 72.8 | -12.91 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.08 | 1.15 | -0.07 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 47.2x | 113.1x | -65.90 | EW | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $54.44B | $513.86B | -$459.42B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | EW REV | ABBV REV | EW GROSS % | ABBV GROSS % | EW FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $6.07B | $61.16B | 78.0% | 70.2% | $1.33B | $17.82B |
| FY 2024 | $5.44B | $56.33B | 79.5% | 70.0% | $289.9M | $17.83B |
| FY 2023 | $5.01B | $54.32B | 44.0% | 44.0% | $670.4M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
EW // BETA 1.08
ABBV // BETA 1.15